[Abdominal obesity: a health threat].
Abdominal obesity is often associated with a constellation of comorbidities that include central adiposity, insulin resistance, dyslipidemia, and hypertension. Clinical evaluations should include a measurement of waist circumference, which is a good marker of abdominal obesity. Abdominal obesity is closely associated with an elevated outflow of free fatty acids from the visceral fat compartment and dysregulation of adipokine expression, accompanied by increased inflammation. The most serious consequences of abdominal obesity are coronary heart disease and stroke. It is also associated, however, with polycystic ovary syndrome and hepatic steatosis. Weight reduction and increased physical activity should be recommended to patients with a high waist circumference. Patients with abdominal obesity and other classic risk factors are at high cardiovascular risk and require strict monitoring of their blood pressure, LDL-c, and blood glucose. New pharmacological strategies might help manage both abdominal obesity and its metabolic consequences.
Bruckert
Eric
E
Service d'endocrinologie-métabolisme, Hôpital Pitié-Salpêtrière, F-75013 Paris, France. eric.bruckert@psl.aphp.fr
D052242:Adiponectin / Q000378:metabolism; D003327:Coronary Disease / Q000209:etiology / Q000517:prevention & control; D015444:Exercise; D006801:Humans; D007333:Insulin Resistance; D050152:Intra-Abdominal Fat; D009765:Obesity / Q000150:complications* / Q000628:therapy; D012307:Risk Factors; D020521:Stroke / Q000209:etiology / Q000517:prevention & control; D015431:Weight Loss
D052242:Adiponectin